Does irbesartan improve the risk of death or hospitalization for cardiovascular causes among patients with HF and PEF?

Current Cardiology Reports

Volumn 12, Issue 3, 2010, Pages 193-195

  Lindenfeld, Jo Ann ^a  

^a UNIVERSITY OF COLORADO   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

AMINO TERMINAL PRO BRAIN NATRIURETIC PEPTIDE; BETA ADRENERGIC RECEPTOR BLOCKING AGENT; DIPEPTIDYL CARBOXYPEPTIDASE INHIBITOR; DIURETIC AGENT; IRBESARTAN; PLACEBO;

BLOOD PRESSURE REGULATION; CLINICAL TRIAL; DIABETES MELLITUS; DIASTOLIC BLOOD PRESSURE; DRUG DOSE TITRATION; DRUG WITHDRAWAL; FOLLOW UP; GLOMERULUS FILTRATION RATE; HEART ARRHYTHMIA; HEART ATRIUM FIBRILLATION; HEART FAILURE; HEART INFARCTION; HEART LEFT VENTRICLE EJECTION FRACTION; HOSPITALIZATION; HUMAN; HYPERKALEMIA; HYPERTENSION; HYPOTENSION; ISCHEMIC HEART DISEASE; KIDNEY DYSFUNCTION; MORTALITY; NOTE; QUALITY OF LIFE; RISK ASSESSMENT; STROKE; SYSTOLIC BLOOD PRESSURE; TREATMENT OUTCOME; UNSTABLE ANGINA PECTORIS;

EID: 77956392401     PISSN: 15233782     EISSN: None     Source Type: Journal    
DOI: 10.1007/s11886-010-0099-4     Document Type: Note

References (4)

1. Yusuf S, Pfeffer MA, Swedberg K, et al.: Effects of candesartan in patients with chronic heart failure and preserved left-ventricular ejection fraction: The CHARM-Preserved Trial. Lancet 2003, 362:777-781.
2. Cleland JG, Tendera M, Adamus J, et al.: The perindopril in elderly people with chronic heart failure (PEP-CHF) study. Eur Heart J 2006, 27:2338-2345.
3. Benedict CR, Weiner DH, Johnstone DE, et al.: Comparative neurohormonal responses in patients with preserved and impaired left ventricular ejection fraction: Results of the Studies of Left Ventricular Dysfunction (SOLVD) Registry. The SOLVD Investigators. J Am Coll Cardiol 1993, 22(4 Suppl A):146A-153A.
4. Kitzman DW, Little WC, Brubaker PH, et al.: Pathophysiological characterization of isolated diastolic heart failure in comparison to systolic heart failure. JAMA 2002, 288:2144-2150.